AbbVie Logs 3Q Sales Growth on Higher Immunology, Oncology Results
October 30 2020 - 8:37AM
Dow Jones News
By Matt Grossman
AbbVie Inc. Friday posted higher profit and revenue in the
latest quarter year over year as AbbVie saw growth in its
immunology and oncology segments.
The North Chicago, Ill.-based pharmaceutical company recorded a
third-quarter profit of $2.31 billion, or $1.29 a share, compared
with a profit of $1.88 billion, or $1.26 a share, in the same
three-month period a year earlier.
On an adjusted basis the company's profit was $2.83 a share.
Analysts surveyed by FactSet were expecting an adjusted profit of
$2.76 a share.
AbbVie's revenue was $12.9 billion, an increase from $8.48
billion in last year's third quarter. Analysts had forecast revenue
of $12.72 billion.
Revenue from AbbVie's immunology portfolio rose 4.1% to $5.14
billion, AbbVie said. Hematologic oncology revenue grew nearly 17%
to $1.72 billion. Aesthetics revenue, which includes Botox sales,
decreased 3.1% to $967 million.
Chief Executive Richard A. Gonzalez said results from growth
products such as Skyrizi, Rinvoq and Ubrelvy were tracking above
AbbVie's expectations, and the company's aesthetics portfolio was
showing a V-shaped recovery following a decline during the Covid-19
pandemic.
AbbVie said its dividend will rise to $1.30 a share for the
dividend payable on Feb. 16 of next year, a 10% increase.
The company forecast full-year adjusted earnings per share of
$10.47 to $10.49, higher than its previous guidance of $10.35 to
$10.45 a share.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 30, 2020 08:22 ET (12:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
